Case report of a recurrent resected glucagonoma.

Case report General surgery Glucagonoma Neuroendocrine tumor

Journal

Annals of medicine and surgery (2012)
ISSN: 2049-0801
Titre abrégé: Ann Med Surg (Lond)
Pays: England
ID NLM: 101616869

Informations de publication

Date de publication:
May 2022
Historique:
received: 06 03 2022
revised: 06 04 2022
accepted: 06 04 2022
entrez: 31 5 2022
pubmed: 1 6 2022
medline: 1 6 2022
Statut: epublish

Résumé

Glucagonoma is a rare neuroendocrine tumor (NET). Most glucagonomas are in the tail or body of the pancreas and are diagnosed at a metastatic stage. We report a case of an early recurrence after surgical resection of a glucagonoma and its management. We present a case of a 44-year-old female patient with no medical and surgical history, operated on in May 2018 for pancreatic glucagonoma revealed by skin necrolytic migratory erythema. The patient was regularly monitored by clinical exams and CT scans. In December 2020 (31 months postoperatively), we noticed the recurrence of the cutaneous lesions.Admission laboratory measurements demonstrated hyperglycemia as well as elevated blood Glucagon levels. Explorations showed 3 retro-pancreatic lesions. Based on these findings, we concluded that it was a recurrence of her glucagonoma. The patient was operated on by median laparotomy We performed a warshow's procedure.Pathology confirmed the endocrine nature of the 3 nodules. We are currently 6 months behind the surgery. The examination is strictly normal with no recurrence of the skin lesions so far. Surgical resection on a recurrent glucagonoma is what is unique in our case as we haven't found any case in the literature to our knowledge.What is also unique about our case is both the local aspect of the recurrence and the multiplicity of the tumors observed as multiple nodules around the tail of the pancreas. These lesions were not metastatic lymph nodes as confirmed by pathology. Probably it was an effraction of the big tumor at enucleation. Due to its rareness, there is no clear consensus on the management of glucagonomas therefore we chose to write our case in order to further enrich the literature to achieve one-day guidelines for glucagonomas treatment.

Identifiants

pubmed: 35638031
doi: 10.1016/j.amsu.2022.103604
pii: S2049-0801(22)00364-8
pmc: PMC9142409
doi:

Types de publication

Case Reports

Langues

eng

Pagination

103604

Informations de copyright

© 2022 The Authors. Published by Elsevier Ltd on behalf of IJS Publishing Group Ltd.

Références

Neuroendocrinology. 2016;103(2):153-71
pubmed: 26742109
Dig Surg. 1999;16(1):68-71
pubmed: 9949270
J Eur Acad Dermatol Venereol. 2016 Dec;30(12):2016-2022
pubmed: 27422767
Int J Surg. 2020 Dec;84:226-230
pubmed: 33181358
J Pancreat Cancer. 2018 May 01;4(1):11-16
pubmed: 30631852

Auteurs

Ouadi Yacine (O)

Department of Surgery, A La Rabta, Tunis, Tunisia.
Faculty of Medicine of Tunis, Tunis El Manar University, Tunis, Tunisia.

Feryel Letaief Ksontini (FL)

Faculty of Medicine of Tunis, Tunis El Manar University, Tunis, Tunisia.

Ahmed Ben Mahmoud (A)

Department of Surgery, A La Rabta, Tunis, Tunisia.
Faculty of Medicine of Tunis, Tunis El Manar University, Tunis, Tunisia.

Houcine Magherbi (H)

Department of Surgery, A La Rabta, Tunis, Tunisia.
Faculty of Medicine of Tunis, Tunis El Manar University, Tunis, Tunisia.

Samir Fadhel Fterich (SF)

Department of Surgery, A La Rabta, Tunis, Tunisia.
Faculty of Medicine of Tunis, Tunis El Manar University, Tunis, Tunisia.

Montasser Kacem (M)

Department of Surgery, A La Rabta, Tunis, Tunisia.
Faculty of Medicine of Tunis, Tunis El Manar University, Tunis, Tunisia.

Classifications MeSH